Secukinumab: 12 agencies, 2015–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 10.5 years, from 19 Feb 2015 at AWMSG (Wales) to 29 Aug 2025 at PHARMAC (New Zealand).
CONITEC (Brazil) changed its position: recommended on 25 Dec 2017, not recommended by 2 Jun 2021.
Every one of the eight highest-volume agencies in this archive has a record for secukinumab.
Not every gap is a refusal: for secukinumab, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 23 of 79 records date from 2023 or later.
The programme is broad: 22 distinct indication wordings are recorded for secukinumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
17 of these 79 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess secukinumab, on 19 Feb 2015; CIPM (Spain) did not open a file until 21 Feb 2024 — an unusually long tail of 9 years between the earliest and latest system to look at it.
The record arrives in waves: 11 separate years each carry two or more decisions, spread across 11 years in total.
11 of the 12 agencies here assessed secukinumab more than once, PBAC (Australia) most often at 17 entries — repeat review is the norm for this molecule rather than the exception.
secukinumab has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for secukinumab reads 39 recommended, 16 not recommended, 9 restricted and 5 no benefit, with 10 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 29 Aug 2025 | moderate to severe hidradenitis suppurativa, first-line biologic treatment | PTAC advice: Decline | source |
| PBAC (Australia) | 2025 | Non-radiographic axial spondyloarthritisSevere active psoriatic arthritisSevere psoriatic arthritisAnkylosing spondylitisActive ankylosing spondylitisSevere chronic plaqu… | The PBAC extended the March 2022 recommendation for this drug for a further 12 months. | source |
| DMC (Denmark) | 26 Mar 2025 | Aktiv moderat til svær hidrosadenitis suppurativa | Anbefalet | source |
| CIPM (Spain) | 21 Feb 2024 | Indicaciones terapéuticas autorizadas: Tratamiento de la psoriasis en placas de moderada a grave en adultos candidatos… | financed by the SNS · art. 92 a, c | source |
| HAS (France) | 14 Feb 2024 | Re-examination following new data | SMR substantial · ASMR V | source |
74 further decisions for secukinumab, across 11 agencies, are not shown here. They link to 42 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
- lenalidomide — same ATC class L04A — Immunosuppressants
Coverage: 79 decisions for secukinumab from 12 agencies, 2015 to 2025. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.